The question behind this investigation
I want a price comparison to answer a practical question: what would someone have to pay now, and what payment follows? A starting figure often answers neither completely. A low medication advertisement may refer to an introductory period, a long prepaid term or a fee for care without the prescription. We selected three services already covered in our reviews—Found, Enhance.MD and CoreAge Rx—and examined named public offers rather than combining every headline into a cheapest-provider ranking. The sample is intentionally small. It tests how well the published billing details support a budget; it does not represent the whole market or evaluate clinical outcomes.
Eleven offers, three different kinds of uncertainty
The explorer records three Found offers, six Enhance.MD offers and two CoreAge Rx starting offers. Each row preserves its product, billing pattern, inclusions and exclusions. Five rows contain a first-payment figure and a renewal figure: the three Found offers and Enhance’s two short terms. Four longer Enhance terms publish an equivalent periodic amount without establishing the exact checkout invoice in the information we captured. The two CoreAge starting offers do not establish a complete first and renewal bill. Those six missing totals remain missing. A reader can still use the named offer to ask a specific question, but an unconfirmed invoice should never enter an arithmetic comparison as zero.
| Measure | Recorded result |
|---|---|
| Named offers examined | 11 from 3 providers |
| First and renewal figures recorded | 5, including conditional introductions |
| Both invoice totals unconfirmed | 6; not treated as zero |
| Reference amount changed on recheck | 0 of 3 selected review references |
Purpose-selected sample checked October 14, 2026. Results describe public information, not completed checkouts or market-wide rates.
The first period and renewal need separate columns
Found’s compounded semaglutide offer lists $179 for the first four weeks and $289 afterward; its tirzepatide offer lists $219 followed by $359. Those introductions do not apply to every later period. Its $149 branded-plan care membership excludes branded medication and applicable labs, so it has a different scope even when its opening fee is lower. Enhance advertises first-order discounts alongside its short-term product prices; the recorded first-payment examples depend on that advertised discount applying. Our review keeps that condition visible. The practical habit is to obtain the offer name, the introductory eligibility rule and the next recurring amount together, before estimating a multi-period budget.
A lower equivalent is not a smaller checkout commitment
Enhance’s Core product ladder shows lower equivalent amounts for longer terms. Its published $237 equivalent over a 12-week term produces an undiscounted arithmetic illustration of $711 across three four-week periods. That multiplication is useful for understanding the term, but it is not an independently confirmed checkout invoice. Discounts, rounding and applicable charges can affect the actual first payment. The same distinction matters for the 24- and 48-week offers. A 48-week term also should not be described as a full 52-week year merely because the merchant labels it twelve months. Our explorer displays the advertised equivalent separately and leaves the unverified invoice blank.
What the dated records actually establish
We retained the reference amounts from the earlier published review records and rechecked the corresponding sources on October 14. Found remained $149 per four-week branded-care period, Enhance’s short Core reference remained $249 per four weeks and CoreAge’s selected semaglutide product reference remained $79 per advertised month. No change in these three reference amounts was observed in this recheck. That finding is narrow: it is not proof that every offer, discount, subscription condition or individual quote remained the same. These records describe our published reference and its source recheck; they are not invoices from completed patient purchases, a long-term price trend or a guarantee that a reader will receive the same offer.
| Provider | Earlier source check | Reference amount and scope | October 14 recheck |
|---|---|---|---|
| Found | 2026-10-13 | $149 /4 weeks · Branded-plan cash-pay membership | Same reference amount on recheck |
| Enhance.MD | 2026-10-13 | $249 /4 weeks · Single-period GLP-1 Core subscription | Same reference amount on recheck |
| CoreAge Rx | 2026-10-13 | $79 /month · Advertised semaglutide starting price | Same reference amount on recheck |
The earlier date identifies the retained review source record. Scope and conditions remain part of each amount.
Conflicting pages deserve a written answer
CoreAge’s selected semaglutide product page and its navigation present different starting figures. Its FAQ and policy language also do not make every cancellation and refund question disappear. Our review explains the conflict and the explorer does not turn the $79 reference into a confirmed first invoice. This is where a comparison should become more specific, not more confident. Ask which offer controls your checkout, whether the medicine and supply match the advertisement, how renewals happen and which charges can be retained after cancellation. Keep the written answer with the actual terms. A marketing statement and a contract clause may describe different situations; neither should be silently discarded to simplify a table.
Use the records to prepare your next question
Start with the exact medication proposed by your clinician and compare the same quantity, service scope and billing period. Then separate care, prescription, labs, shipping and one-time charges. Ask for both the first invoice and the renewal schedule; if a longer term is prepaid, obtain the total commitment and applicable refund conditions. Our calculators can organize those numbers once you have them, but cannot fill an unknown charge or decide which treatment fits you. We will add dated observations as sources are checked, preserving scope when a published offer changes. The useful result of this investigation is a more complete question for the provider, rather than a universal winner based on a headline price.
Work through the actual offer
Explore the 11 named offers · Estimate introduction and renewal totals · Assess prepayment commitment
Evidence and limits
Sources: Found plan-specific offer terms; Enhance.MD Core and Advanced product terms; CoreAge Rx semaglutide and tirzepatide product pages, FAQ and subscription/refund policies. Find the analysis in our Found, Enhance.MD and CoreAge Rx reviews. The sample was chosen for differing billing models and existing researched coverage, including commercial partners. It is not random, comprehensive or a measure of typical patient spending.